Global Influenza Vaccine Market Growth 2025-2031

The global Influenza Vaccine market size is predicted to grow from US$ 9555 million in 2025 to US$ 13360 million in 2031; it is expected to grow at a CAGR of 5.7% from 2025 to 2031.

Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.

Market Driver:The Influenza Vaccine market is driven by the rising global awareness of flu prevention and increasing government initiatives to promote vaccination programs. Seasonal influenza poses a significant public health burden, leading to hospitalizations and fatalities, particularly among high-risk populations such as the elderly, young children, and immunocompromised individuals. Governments and health organizations, including the WHO and CDC, actively support annual flu vaccination campaigns to reduce disease transmission. Additionally, advancements in vaccine technology, such as cell-based and recombinant influenza vaccines, are improving vaccine efficacy and production efficiency, further driving market growth.

Market Challenge:Despite its importance, the Influenza Vaccine market faces challenges related to vaccine hesitancy, manufacturing constraints, and viral mutations. Public skepticism regarding vaccine safety and effectiveness, fueled by misinformation, hampers vaccination rates in some regions. Additionally, influenza viruses undergo frequent genetic mutations, requiring annual vaccine updates and posing challenges in predicting dominant strains. Manufacturing influenza vaccines is also time-sensitive, as traditional egg-based production methods have limitations in scalability and response speed during pandemics. These factors can impact supply chain stability and overall vaccine accessibility.

Global key players of Pandemic Influenza Vaccine include Sanofi, CSL and GSK, etc. The top five players hold a share about 80%. North America is the largest market, has a share about 50%.

LP Information, Inc. (LPI) ' newest research report, the “Influenza Vaccine Industry Forecast” looks at past sales and reviews total world Influenza Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Influenza Vaccine sales for 2025 through 2031. With Influenza Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Influenza Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Influenza Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Influenza Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Influenza Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Influenza Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Influenza Vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of Influenza Vaccine market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine

Segmentation by Application:
6 Months to 3 Years
> 3 Years

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi
CSL
GSK
Viatris
AstraZeneca
Hualan Bio
Changchun Institute of Biological
Sinovac
BCHT
Jiangsu GDK
KM Biologics

Key Questions Addressed in this Report

What is the 10-year outlook for the global Influenza Vaccine market?

What factors are driving Influenza Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Influenza Vaccine market opportunities vary by end market size?

How does Influenza Vaccine break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.